drugset / Trial / NCT01960374

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

NCT01960374

Phase 1 Completed 117 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

The purpose of the study is to assess the safety, tolerability and PK of selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in healthy male Japanese and non-Japanese Asian volunteers following administration of a single dose. Standard safety assessments including ECGs, vital signs, blood/urine safety tests, PK samples and monitoring of adverse events and an optional exploratory pharmacogenetics will be performed.

Timeline

Start
2013-10
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 25 mg Oral
Subject Selumetinib Small molecule 50 mg Oral
Subject Selumetinib Small molecule 75 mg Oral

Indications

No indication recorded.